Table 2 Adverse events
Event | Grade 3/4 (n) | % | Total (n) | % |
|---|---|---|---|---|
Any event | 13 | 76% | 17 | 100% |
Anemia | 4 | 24% | 14 | 82% |
Anorexia | 0 | 0% | 6 | 35% |
Arthralgia | 1 | 6% | 7 | 41% |
Chills | 0 | 0% | 10 | 59% |
Constipation | 0 | 0% | 4 | 24% |
Cough | 0 | 0% | 3 | 18% |
Decreased urine output | 1 | 6% | 1 | 6% |
Diarrhea | 1 | 6% | 7 | 41% |
Dry skin | 0 | 0% | 15 | 88% |
Dyspnea | 0 | 0% | 3 | 18% |
Edema | 0 | 0% | 14 | 82% |
Fatigue | 0 | 0% | 14 | 82% |
Fever | 0 | 0% | 5 | 29% |
Headache | 0 | 0% | 7 | 41% |
Hyperglycemia | 1 | 6% | 6 | 35% |
Hyperkalemia | 1 | 6% | 4 | 24% |
Hypermagnesiumia | 1 | 6% | 1 | 6% |
Hypertension | 1 | 6% | 2 | 12% |
Hyperuricemia | 2 | 12% | 4 | 24% |
Hypoalbuminemia | 8 | 47% | 14 | 82% |
Hypoglycemia | 0 | 0% | 5 | 29% |
Hyponatremia | 1 | 6% | 2 | 12% |
Hypophosphatemia | 0 | 0% | 3 | 18% |
Hypotension | 0 | 0% | 7 | 41% |
Increased alanine aminotransferase | 0 | 0% | 3 | 18% |
Increased alkaline phosphatase | 0 | 0% | 3 | 18% |
Increased aspartate aminotransferase | 0 | 0% | 5 | 29% |
Increased bilirubin | 2 | 12% | 6 | 35% |
Increased Creatinine | 2 | 12% | 6 | 35% |
Injection site reaction | 0 | 0% | 5 | 29% |
Lymphopenia | 3 | 18% | 4 | 24% |
Myalgia | 0 | 0% | 10 | 59% |
Nausea | 0 | 0% | 11 | 65% |
Pain | 1 | 6% | 12 | 71% |
Peripheral sensory neuropathy | 0 | 0% | 7 | 41% |
Pruritus | 1 | 6% | 12 | 71% |
Rash | 1 | 6% | 8 | 47% |
Thrombocytopenia | 1 | 6% | 2 | 12% |
Tinnitus | 0 | 0% | 3 | 18% |
Ventricular tachycardia | 1 | 6% | 2 | 12% |
Vomiting | 0 | 0% | 7 | 41% |
Weight loss | 0 | 0% | 3 | 18% |